trending Market Intelligence /marketintelligence/en/news-insights/trending/Ln9DErqFdxoSKCHWp6Zhxg2 content esgSubNav
In This List

Abattis Bioceuticals to acquire Green Tree Therapeutics

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Infographic: The Big Picture 2024 – Energy Transition Outlook

Case Study

An Oil and Gas Company's Roadmap for Strategic Insights in a Quickly Evolving Regulatory Landscape


Abattis Bioceuticals to acquire Green Tree Therapeutics

Medical cannabis company Abattis Bioceuticals Corp. is looking to acquire Green Tree Therapeutics, which sells vaporizers across North America.

The company has entered a nonbinding agreement to buy Winston Resources Inc., which owns Green Tree Therapeutics.

Abattis plans to issue 5.5 million of its shares to Green Tree shareholders and another 25 million shares to Winston Resources as consideration for the purchase.

The Green Tree Therapeutics buy will help provide Abattis with an entry point into the vaporizers market, the company's CEO, Rob Abenante, said in a statement.